Thompson Coburn is pleased to serve as a sponsor of the 10th Annual National Institute on the Civil False Claims Act and Qui Tam Enforcement. The Institute will bring together experts from all areas – U.S. Department of Justice, state attorneys general offices, federal agencies, leading defense and plaintiff firms – to discuss this ever-growing area of litigation and enforcement. The Institute will take place at the Park Hyatt Hotel in Washington, D.C., June 4 – 6.
On Thursday, June 5, Business Litigation partner Claire Schenk will be part of a panel discussion on “Recent Developments on Damages and Penalties.” The panel will focus on the calculation and proof of FCA damages, particularly in cases where the damages are not easily ascertainable, as well as the assessment of civil penalties. The group will also discuss the effect of United States ex rel. Bunk v. Gosselin World Wide Moving, a Fourth Circuit decision on the relationship between government loss and penalties.
Claire concentrates her practice in the areas of Health Care Fraud and Abuse, False Claims Act litigation and other complex white-collar civil litigation. Drawing upon her 14-year history with the Department of Justice and service as a Civil Chief, Claire represents and advises health care providers, registrants under the Controlled Substances Act and government contractors. She currently serves as the court-appointed Receiver for the Acartha Group entities in litigation instituted by the SEC in the Eastern District of Missouri. Claire has handled federal equity Receivership work for Small Business Investment Companies throughout her career.
Thompson Coburn is a sponsor for a reception that will follow Thursday’s presentations. Click here for more details and the full agenda on this event.
Although we would like to hear from you, we cannot represent you until we know that doing so will not create a conflict of interest. Also, we cannot treat unsolicited information as confidential. Accordingly, please do not send us any information about any matter that may involve you until you receive a written statement from us that we represent you (an ‘engagement letter’).
By clicking the ACCEPT button, you agree that we may review any information you transmit to us. You recognize that our review of your information, even if you submitted it in a good faith effort to retain us, and, further, even if you consider it confidential, does not preclude us from representing another client directly adverse to you, even in a matter where that information could and will be used against you. Please click the ACCEPT button if you understand and accept the foregoing statement and wish to proceed.